RNS Number : 5742T
Rentokil Initial PLC
20 March 2023
 

Rentokil Initial plc (the Company)

The Company hereby announces that David Frear, Non-Executive Director, purchased 500 American Depositary Shares (ADSs) in the Company at a price of US$33.05 per ADS on 17 March 2023. Each ADS is equivalent to five of the Company's ordinary shares of one pence each.

 

The notification set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

David Frear

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Rentokil Initial plc American Depositary Shares

 

 

CUSIP: 760125104

b)

 

Nature of the transaction

 

 

Purchase of American Depositary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

$33.05

 

500

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

500

 

$16,525.00

e)

 

Date of the transaction

 

17 March 2023

f)

 

Place of the transaction

 

New York Stock Exchange

 

Enquiries:

 

Catherine Stead, Company Secretary              Rentokil Initial plc             +44 (0)7826 533700

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBLGDXUSDDGXG